AU2018236286B2 - Forms and compositions of a MK2 inhibitor - Google Patents

Forms and compositions of a MK2 inhibitor Download PDF

Info

Publication number
AU2018236286B2
AU2018236286B2 AU2018236286A AU2018236286A AU2018236286B2 AU 2018236286 B2 AU2018236286 B2 AU 2018236286B2 AU 2018236286 A AU2018236286 A AU 2018236286A AU 2018236286 A AU2018236286 A AU 2018236286A AU 2018236286 B2 AU2018236286 B2 AU 2018236286B2
Authority
AU
Australia
Prior art keywords
compound
acid
disease
complex
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018236286A
Other languages
English (en)
Other versions
AU2018236286A1 (en
Inventor
Jianxin HAN
Lianfeng Huang
Uday Jain
Ying Li
John MALONA
Kevin MOLTER
Chittari Pabba
Alexander L. Ruchelman
Jean Xu
Daozhong Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2018236286A1 publication Critical patent/AU2018236286A1/en
Application granted granted Critical
Publication of AU2018236286B2 publication Critical patent/AU2018236286B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: CELGENE CAR LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
AU2018236286A 2017-03-16 2018-03-15 Forms and compositions of a MK2 inhibitor Ceased AU2018236286B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
AU2018236286A1 AU2018236286A1 (en) 2019-09-19
AU2018236286B2 true AU2018236286B2 (en) 2022-02-17

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236286A Ceased AU2018236286B2 (en) 2017-03-16 2018-03-15 Forms and compositions of a MK2 inhibitor

Country Status (8)

Country Link
US (2) US10882867B2 (https=)
EP (1) EP3595658A4 (https=)
JP (2) JP2020514360A (https=)
CN (1) CN110678178B (https=)
AU (1) AU2018236286B2 (https=)
CA (1) CA3054823A1 (https=)
MX (1) MX393600B (https=)
WO (1) WO2018170199A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
WO2018170204A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0894003A4 (en) * 1996-04-12 2000-10-04 Bristol Myers Squibb Co N-FORMYL HYDROXYLAMINE-BASED COMPOUNDS SUITABLE AS INCEPTIENTS OF THE ACE ENZYME AND / OR ENDOPEPTIDASE NEP
CN1747949A (zh) * 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
EP2699572B1 (en) * 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
US9695193B2 (en) * 2013-06-26 2017-07-04 The Trustees Of Columbia University In The City Of New York Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2020514360A (ja) 2020-05-21
WO2018170199A1 (en) 2018-09-20
CN110678178A (zh) 2020-01-10
US11629153B2 (en) 2023-04-18
CA3054823A1 (en) 2018-09-20
EP3595658A1 (en) 2020-01-22
EP3595658A4 (en) 2020-11-25
US10882867B2 (en) 2021-01-05
CN110678178B (zh) 2023-10-03
US20210198276A1 (en) 2021-07-01
US20200148701A1 (en) 2020-05-14
MX2019010643A (es) 2019-10-17
AU2018236286A1 (en) 2019-09-19
JP2023017840A (ja) 2023-02-07
MX393600B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
AU2018236286B2 (en) Forms and compositions of a MK2 inhibitor
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
AU2018236290A1 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
JP2025538371A (ja) 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
TWI771280B (zh) 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR102849420B1 (ko) Jak 억제 화합물의 지나포에이트염
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
CA3041854C (en) PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
JP2026508943A (ja) 結晶形態
US10544137B2 (en) PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
CN118251400A (zh) Axl激酶抑制剂的盐、其制备方法和用途
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
US20210188823A1 (en) Method for Producing Diarylpyridine Derivatives
WO2019057121A1 (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
WO2025217647A1 (en) Stat6 degraders and uses thereof
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2025236004A1 (en) Stat6 inhibitors and uses thereof
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
EA044028B1 (ru) Ксинафоатная соль соединения, ингибирующего jak
BR112019009448B1 (pt) Cristal de um composto, seu uso e composição farmacêutica

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HAN, JIANXIN; HUANG, LIANFENG; JAIN, UDAY; LI, YING; MALONA, JOHN; MOLTER, KEVIN; PABBA, CHITTARI; RUCHELMAN, ALEXANDER L.; XU, JEAN AND ZOU, DAOZHONG

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER OWNER(S): CELGENE CAR LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired